<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200714048106N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-29</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>The effect of L-carnitine on erectile dysfunction</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of adding oral vial L-carnitine on the efficacy of sildenafil citrate tablets in the treatment of erectile dysfunction in men with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49648</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 40 male patients with type 2 diabetes referred to Imam Reza (AS) Diabetes Clinic who complain of erectile dysfunction and this disorder has been approved by a urologist who collaborated with the project, if they have the conditions to enter the study and Using block randomization method and using software are divided into two groups of intervention and control, Blinding description: Blindness, due to its double blindness, is such that in this study, only the specialist in charge of the study is aware of the type of study and the study groups, while patients are not aware of the type of drug used. Also, the intern in charge of the project who is responsible for filling out the questionnaire; He is not aware of the type of groups according to the drug used and only recognizes the groups based on A and B, and the form of demographic information and the International Erectile Dysfunction Questionnaire 5 (IIEF5) are completed for both groups. Patients are randomly divided into intervention and control groups, and both groups receive sildenafil tablets, but the intervention group receives vials of L-carnitine and the placebo control group receives the same vial of L-carnitine, both of which are manufactured by BSK Bio-Fermentation. .receive sildenafil tablets, but the intervention group is vial L-carnitine and the placebo control group is similar to vial L-carnitine, both of which are manufactured by B. They receive bio-fermentation.</study_design>
      <phase>3</phase>
      <hc_freetext>Erectile dysfunction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: First, the form containing demographic information and the International Erection Questionnaire for patients are completed, and then they receive the sildenafil tablet in addition to the L-carnitine vial manufactured by BSKa Fermentation Company. Sildenafil Citrate 100 mg tablets half an hour before sexual intercourse with oral L-carnitine vial alone or dissolved in 1 g of liquid beverage or food (oral BSK vial of BSK brand made by Iran Bio Fermentation Company) in Consumed during the day. The study will continue for 4 weeks. After 4 weeks, the International Erectile Dysfunction Questionnaire 5 (IIEF5) will be completed again in similar conditions. Intervention 2: Control group: First, the form containing demographic information and the International Erection Questionnaire for patients was completed and patients treated with sildenafil citrate tablets at a dose of 100 mg half an hour before each sexual intercourse with an oral placebo vial with a drink (made by Iran Bio Fermentation Company). Will take. The study will continue for 4 weeks and after 4 weeks, the International Erectile Dysfunction Questionnaire 5 (IIEF5) will be completed again in similar conditions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hesam-o-din Rezae</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar-e-azam Complex, Basij Sq., Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3639</telephone>
        <email>hesameddinrezaei13740624@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hesam-o-din Rezae</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar-e-azam Complex, Basij Sq., Sardasht Town</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176341</zip>
        <telephone>+98 86 3417 3639</telephone>
        <email>hesameddinrezaei13740624@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Erectile dysfunction
Diagnose type 2 diabetes for at least three months
No history of taking sildenafil citrate or L-carnitine during the previous three months</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Patients with spinal cord injury
Patients treated with sildenafil citrate or L-carnitine.
Severe kidney failure
Known liver disease
Erectile dysfunction (ED) with known and treated origin of psychological disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Male erectile dysfunction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: First, the form containing demographic information and the International Erection Questionnaire for patients are completed, and then they receive the sildenafil tablet in addition to the L-carnitine vial manufactured by BSKa Fermentation Company. Sildenafil Citrate 100 mg tablets half an hour before sexual intercourse with oral L-carnitine vial alone or dissolved in 1 g of liquid beverage or food (oral BSK vial of BSK brand made by Iran Bio Fermentation Company) in Consumed during the day. The study will continue for 4 weeks. After 4 weeks, the International Erectile Dysfunction Questionnaire 5 (IIEF5) will be completed again in similar conditions.</i_keyword>
      <i_keyword>Control group: First, the form containing demographic information and the International Erection Questionnaire for patients was completed and patients treated with sildenafil citrate tablets at a dose of 100 mg half an hour before each sexual intercourse with an oral placebo vial with a drink (made by Iran Bio Fermentation Company). Will take. The study will continue for 4 weeks and after 4 weeks, the International Erectile Dysfunction Questionnaire 5 (IIEF5) will be completed again in similar conditions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Erectile function. Timepoint: After 4 weeks. Method of measurement: International index of erectile function 5 (IIEF5).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-10</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Payambar-e-azam Complex, Basij Sq., Sardasht Town Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
